Результаты поиска

Dissecting the role of bone marrow stromal cells on bone metastases.

Tumor-induced bone disease is a dynamic process that involves interactions with many cell types. Once metastatic cancer cells reach the bone, they are in contact with many different cell types that are present in the cell-rich bone marrow. These cells include the immune cells, myeloid cells, fibroblasts, osteoblasts, osteoclasts, and mesenchymal stem cells. Each of these cell populations can influence the behavior or gene expression of both the tumor cells and the bone microenvironment. Additionally, the tumor itself can alter the behavior of these bone marrow cells which further alters both t

Совпадение в полном тексте источника
… Bisphosphonates (including zoledronate, alendronate, ibandronate, etc.) have been highly successful for reducing skeletal related events in patients with osteoporosis and with tumor-induced bone destruction [ 39 , 40 ]. …

Applied information retrieval and multidisciplinary research: new mechanistic hypotheses in complex regional pain syndrome.

BackgroundCollaborative efforts of physicians and basic scientists are often necessary in the investigation of complex disorders. Difficulties can arise, however, when large amounts of information need to reviewed. Advanced information retrieval can be beneficial in combining and reviewing data obtained from the various scientific fields. In this paper, a team of investigators with varying backgrounds has applied advanced information retrieval methods, in the form of text mining and entity relationship tools, to review the current literature, with the intention to generate new insights into th

Совпадение в полном тексте источника
… Pain 2003 102 297 307 12670672 10.1016/S0304-3959(02)00414-1 Grundberg AB Reflex sympathetic dystrophy: treatment with long-acting intramuscular corticosteroids J Hand Surg [Am] 1996 21 667 670 8842963 10.1016/S0363-5023(96)80023-2 Manicourt DH Brasseur JP Boutsen Y Depreseux G Devogelaer JP Role of alendronate …

Pathogenesis and treatment of multiple myeloma bone disease.

Multiple myeloma (Plasma cell myeloma), a malignancy of the plasma cells, exhibits tumor expansion preferentially in the bone marrow and the development of bone-destructive lesions. Multiple myeloma is still an incurable disease with changes in the bone marrow microenvironment in favor of the survival and proliferation of multiple myeloma cells and bone destruction. In this review, we described the recent findings on the regulators involved in the development of myeloma bone diseases, and succinctly summarize currently available therapeutic options and the development of novel bone modifying a

Совпадение в полном тексте источника
… Romosozumab or alendronate for fracture prevention in women with osteoporosis N Engl J Med 377 2017 1417 1427 28892457 10.1056/NEJMoa1708322 115 Cosman F. Crittenden D.B. Adachi J.D. Binkley N. Czerwinski E. Ferrari S. …

Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?

Bone metastases ultimately result from a complex interaction between cancer cells and bone microenvironment. However, prior to the colonization of the bone, cancer cells must succeed through a series of steps that will allow them to detach from the primary tumor, enter into circulation, recognize and adhere to specific endothelium, and overcome dormancy. We now know that as important as the metastatic cascade, tumor cells prime the secondary organ microenvironment prior to their arrival, reflecting the existence of specific metastasis-initiating cells in the primary tumor and circulating osteo

Совпадение в полном тексте источника
… Nitrogen-containing BPs (alkyl-amino BPs: pamidronate, alendronate, ibandronate; heterocyclic BPs: risendronate, ZA) impair the mevalonate pathway by inhibiting the farnesyl diphosphate synthase (FPP synthase), ultimately preventing prenylation of small GTPase signaling proteins vital for normal cellular …

Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice.

Bone is the most common site of metastasis from breast cancer. Bone metastases from breast cancer are associated with skeletal-related events (SREs) including pathological fractures, spinal cord compression, surgery and radiotherapy to bone, as well as bone pain and hypercalcemia, leading to impaired mobility and reduced quality of life. Greater understanding of the pathophysiology of bone metastases has led to the discovery and clinical utility of bone-targeted agents such as bisphosphonates and the receptor activator of nuclear factor kappa-B ligand (RANK-L) antibody, denosumab. Both are now

Совпадение в полном тексте источника
… Class | Simple bisphosphonate | Nitrogen-containing bisphosphonate (N-BP) Structure | | | | | | Generic Name | Etidronate | Clodronate | Pamidronate | Alendronate | Ibandronate | Zoledronic acid Product Name | Didronel ® | Bonefos ® | Aredia ® | Fosamax ® | Bondronat ® | Zometa ® Relative Potency …

Differential Zoledronate Adsorption by Commercially Available Biphasic Calcium Phosphate Bone Substitutes.

Background/Objectives: Osteonecrosis of the jaw, a non-healing wound, is a side effect in patients treated with nitrogen-containing bisphosphonates (e.g., zoledronate) after some oral procedures. Considering zoledronate toxicity in surgical wounds and the capacity of calcium phosphate synthetic compounds to adsorb it, the aim of this work was to demonstrate and elucidate the mechanism underlying this adsorption. Methods: Four different calcium phosphate synthetic bone substitutes were used in this study: AdBone® BCP (0.5-1 mm), Guidor® easy-graft (0.5-1 mm), Maxresorb® (0.5-1 mm) and Maxresorb

Совпадение в полном тексте источника
… Influence of PH on Osteoclasts Treated with Zoledronate and Alendronate Clin. Oral Investig. 2018 23 813 820 10.1007/S00784-018-2505-Z 29876664 47. Steiner G.G. Francis W. Burrell R. Kallet M.P. Steiner D.M. Macias R. The Healing Socket and Socket Regeneration Compend. Contin. Educ. …

Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.

An imbalance between bone resorption and bone formation underlies the devastating osteolytic lesions and subsequent fractures seen in more than 90% of multiple myeloma (MM) patients. Currently, Wnt-targeted therapeutic agents that prevent soluble antagonists of the Wnt signaling pathway, sclerostin (SOST) and dickkopf-1 (DKK1), have been shown to prevent bone loss and improve bone strength in preclinical models of MM. In this study, we show increasing Wnt signaling via a novel anti-low-density lipoprotein receptor-related protein 6 (LRP6) antibody, which potentiates Wnt1-class ligand signaling

Совпадение в полном тексте источника
… Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377:1417–1427. 13. Riddle RC, Diegel CR, Leslie JM, et al. Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition. PLoS One. 2013;8:e63323. 14. …

Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment.

The skeletal system is of paramount importance in advanced stage prostate cancer (PCa) as it is the preferred site of metastasis. Complex mechanisms are employed sequentially by PCa cells to home to and colonize the bone. Bone-resident PCa cells then recruit osteoblasts (OBs), osteoclasts (OCs), and macrophages within the niche into entities that promote cancer cell growth and survival. Since PCa is heavily reliant on androgens for growth and survival, androgen-deprivation therapy (ADT) is the standard of care for advanced disease. Although it significantly improves survival rates, ADT detrime

Совпадение в полном тексте источника
… Nitrogen-containing bisphosphonates, such as alendronate, risedronate, and zoledronic acid, as well as denosumab, a monoclonal antibody to RANKL are all FDA-approved to treat osteoporosis in PCa patients on ADT. …

The Osteoclast in Bone Metastasis: Player and Target.

Bone metastases are frequently the final fate of breast and prostate cancer patients. According to the definition of metastasis as an incurable disease, to date there are no effective treatments for tumor-associated bone metastases and this represents a real challenge for the researchers in the field. The bone is a heterogeneous environment that represents a fertile soil for tumor cells, supporting their growth. Among the different cell types present in the bone, in this review we will focus our attention on the osteoclasts, which are crucial players in the so called “vicious cycle”, a phenome

Совпадение в полном тексте источника
… Nitrogen containing bisphosphonates (i.e., ibandronate, pamidronate, risedronate, alendronate and zoledronate) induce osteoclast apoptosis by interfering with the mevalonate pathway, leading to the accumulation of triphosphoric acid 1-adenosin-5′-y1 ester 3-(3-methylbut-3-enyl) ester (ApppI) and of isopentenyl …

Bone Research Society 2021 Abstracts

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption.

Multiple myeloma (MM) is a malignancy of terminally differentiated B-cells that is localized primarily in the bone marrow (BM) but also can be present in peripheral blood and tissue/organs [...].

Совпадение в полном тексте источника
… Ten Years’ Experience with alendronate for osteoporosis in postmenopausal women N. Engl. J. 2004 350 1189 1199 10.1056/NEJMoa030897 15028823 7. Aapro M. Abrahamsson P.A. Body J.J. Coleman R.E. Colomer R. Costa L. Crinò L. Dirix L. Gnant M. Gralow J. …

From Development, Disease, and Decline: A Review of What Defines an Osteoclast Progenitor.

Our understanding of the different developmental origins of osteoclast progenitors and their respective roles during homeostatic bone remodeling at different skeletal sites as well as their roles within bone regeneration and degenerative conditions is evolving. In this narrative review article, we summarize what is known about the developmental origins, anatomical sources, and markers of osteoclast progenitors. We touch on how osteoclast progenitors vary during different disease contexts, including periodontitis, rheumatoid arthritis, and osteoarthritis. In addition, we also characterize osteo

Совпадение в полном тексте источника
… Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression Bone 2014 66 163 170 10.1016/j.bone.2014.06.009 24933343 135. Su W. Liu G. Liu X. Zhou Y. Sun Q. Zhen G. Wang X. Hu Y. Gao P. Demehri S. …

A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.

Background and Objectives: The aim of this study was to examine how the status of the oral cavity, composition and properties of saliva change in oncological patients with and without Medication-Related Osteonecrosis of the Jaw (MRONJ) undergoing bisphosphonate therapy. Materials and Methods: A retrospective case-control study of 49 oncological patients using bisphosphonates (BPs) was conducted. The study population was divided into two groups-Group I consisted of 29 patients with MRONJ and Group II of 20 patients without MRONJ. The control group consisted of 32 persons without oncological his

Совпадение в полном тексте источника
… Cytotoxic and inflammatory effects of alendronate and zolendronate on human osteoblasts, gingival fibroblasts and osteosarcoma cells. J. Craniomaxillofac. Surg. 2018;46:538–546. doi: 10.1016/j.jcms.2017.12.015. 21. …

Влияет ли остеонекроз челюсти, связанный с лекарствами, на выживание пациентов с множественной миеломой?: Изучение большой базы данных одного центра с использованием искусственного интеллекта.

Помимо случайных клинических испытаний, для отражения клинической реальности необходимо учитывать реальные данные. Однако обработка таких доказательств для большого числа пациентов часто требует значительного времени и усилий. Это особенно касается редких опухолей, таких, как множественная миелома (ММ), или неблагоприятных последствий, которые проявляются еще реже. В таких случаях искусственный интеллект позволяет эффективно обнаруживать пациентов с редкими заболеваниями. One Из этих редких неблагоприятных явлений, наиболее часто обсуждаемых после лечения костной защиты в MM, остеонекроз челюс

Osteocytes: New Kids on the Block for Cancer in Bone Therapy.

The tumor microenvironment plays a central role in the onset and progression of cancer in the bone. Cancer cells, either from tumors originating in the bone or from metastatic cancer cells from other body systems, are located in specialized niches where they interact with different cells of the bone marrow. These interactions transform the bone into an ideal niche for cancer cell migration, proliferation, and survival and cause an imbalance in bone homeostasis that severely affects the integrity of the skeleton. During the last decade, preclinical studies have identified new cellular mechanism

Совпадение в полном тексте источника
… Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N. Engl. J. Med. 2017;377:1417–1427. doi: 10.1056/NEJMoa1708322. 129. Lewiecki E.M., Blicharski T., Goemaere S., Lippuner K., Meisner P.D., Miller P.D., Miyauchi A., Maddox J., Chen L., Horlait S. …

Percutaneous-Reinforced Osteoplasty: A Review of Emerging Treatment Strategies for Bone Interventions.

Percutaneous-reinforced osteoplasty is currently being investigated as a possible therapeutic procedure for fracture stabilization in high-risk patients, primarily in patients with bone metastases or osteoporosis. For these patients, a percutaneous approach, if structurally sound, can provide a viable method for treating bone fractures without the physiologic stress of anesthesia and open surgery. However, the low strength of fixation is a common limitation that requires further refinement in scaffold design and selection of materials, and may potentially benefit from tissue-engineering-based

Совпадение в полном тексте источника
… A comparison of alendronate to varying magnitude PEMF in mitigating bone loss and altering bone remodeling in skeletally mature osteoporotic rats. Bone. 2021;143:115761. doi: 10.1016/j.bone.2020.115761. 7. Bailey S., Vashishth D. …

A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.

The latest pandemic, coronavirus disease-2019 (COVID-19), is associated with high prevalence and easy transmission, which is expanding globally with no conventional treatment or vaccine. The new virus revealed 79% and 50% genomic similarities with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), respectively. Accordingly, since the disease resists testing and adopting new therapeutics, repositioning pre-existing drugs may present a fast and attractive strategy with known safety, characteristics, and dosage used. However, they

Совпадение в полном тексте источника
… with EC50 at 0.46 μM Famotidin Anti-acid H2 antagonist 40 mg–60 mg 8hourly Constipation, diarrhea, fatigue, dizziness, weakness, mood changes, headache, insomnia Heartburn, GERD, and Zollinger-Ellison syndrome ( NCT04504240 ) ( NCT04370262 ) ( NCT04545008 ) Antimicrobials medicines, Acalabrutinib, Alendronate …

Regorafenib Attenuates Osteoclasts Differentiation by Inhibiting the NF-κB, NFAT, ERK, and p38 Signaling Pathways.

Osteolytic diseases such as osteoporosis and neoplastic bone metastases are caused by the excessive activation of osteoclasts. Inhibiting the excessive activation of osteoclasts is a crucial strategy for treating osteolytic diseases. This study investigated the roles and mechanisms of regorafenib, a tyrosine kinase inhibitor, on osteoclasts and osteolytic diseases. We first identified the potential targets and mechanisms of regorafenib on osteoclast-related osteolytic diseases using network pharmacological analysis and molecular docking techniques. Then, we verified its role and mechanism on o

Совпадение в полном тексте источника
… For example, alendronate and zoledronic acid, while effective in reducing osteoclastic activity, 10 can cause gastrointestinal irritation and atypical femur fracture with long-term application. 11 Denosumab, a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor, specifically inhibits osteoclastogenesis …

Impact of Bisphosphonate Therapy on Oral Health in Patients with Breast and Prostate Cancer and Bone Metastases: A Comprehensive Study.

This study investigates the impact of bisphosphonate therapy on the stomatognathic system in 80 patients with cancer of the breast and prostate with bone metastases. Bisphosphonates are integral for managing skeletal complications in these malignancies but are associated with bisphosphonate-related osteonecrosis of the jaw (BRONJ), affecting 0.8-18.5% of patients. BRONJ manifests with pain, neuropathy, tissue swelling, mucosal ulceration, tooth mobility, and abscesses, yet its pathogenesis remains elusive, complicating risk prediction. The research employed comprehensive dental and radiologica

Совпадение в полном тексте источника
… They may also inhibit cartilage tissue resorption, as demonstrated by Kim et al., with alendronate reducing articular cartilage degradation. …

Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment.

As a systemic autoimmune disease, rheumatoid arthritis (RA) usually causes damage not only to joints, but also to other tissues and organs including the heart, kidneys, lungs, digestive system, eyes, skin, and nervous system. Excessive complications are closely related to the prognosis of RA patients and even lead to increased mortality. This article summarizes the serious complications of RA, focusing on its incidence, pathogenesis, clinical features, and treatment methods, aiming to provide a reference for clinicians to better manage the complications of RA.

Совпадение в полном тексте источника
… The study showed that teriparatide resulted in a significantly greater increase in bone mineral density levels and a significant reduction in spinal fractures, compared with the active comparator and the anti-resorptive drug alendronate, and that was confirmed in clinical practice ( 134 ). …